Evidence map›Paper›PMID 40118922›Full record

ArticleScientific reports2025

Determination of both the expression and serum levels of epidermal growth factor and transforming growth factor β1 genes in COVID-19.

Pinar Yildiz Gulhan, Recep Eroz, Cihadiye Elif Ozturk, Dilek Yekenkurul, Hasan Baki Altinsoy, Ege Gulec Balbay, Merve Ercelik, Fatih Davran, Seyma Yildiz

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pinar Yildiz GulhanDepartment of Chest Diseases, Faculty of Medicine, Duzce University, Konuralp Campus, 81010, Duzce, Turkey. pinaryildiz@duzce.edu.tr.
Recep ErozDepartment of Medical Genetics, Aksaray University Medical Faculty, Aksaray, Turkey.
Cihadiye Elif OzturkClinic of Infectious Diseases, İstanbul Cerrahi Hospital, İstanbul, Türkiye.
Dilek YekenkurulDepartment of Infection Diseases, Duzce University Medical Faculty, Duzce, Turkey.
Hasan Baki AltinsoyDepartment of Radiology, Medical Faculty, Duzce University, Duzce, Turkey.
Ege Gulec BalbayDepartment of Chest Diseases, Faculty of Medicine, Duzce University, Konuralp Campus, 81010, Duzce, Turkey.
Merve ErcelikDepartment of Chest Diseases, Faculty of Medicine, Duzce University, Konuralp Campus, 81010, Duzce, Turkey.
Fatih DavranDepartment of Biochemistry, Faculty of Medicine, Duzce University, Duzce, Turkey.
Seyma YildizDeparment of Hematology, Gazi University, Ankara, Turkey.

Funding

The Düzce University coordinatorship of scientific research projects DÜBAP:2020.04.03.1146
6 · The paper itself

Abstract

We aimed to evaluate the effects of both the expression and serum levels of Epidermal growth factor (EGF) and Transforming growth factor-β1 (TGF-β1) genes in patients with different degrees of cellular damage as mild, moderate, severe, and critical illness that can lead to fibrosis caused by SARS-CoV-2. Totally 45 individuals (male: 21(46.67%); female: 24(53.33%)) with COVID-19 infection were included in this study. Four groups were constituted as mild (n = 16)], moderate (n = 10), severe (n = 10), and critical (n = 9) according to the severity of the disease. Blood samples were drawn from the patients, and all of the hemograms, EGF and TGFβ1 gene expression, and serum levels were evaluated. The mean age of individuals was 57.311 ± 18.383 (min: 28, max: 94). Significant differences were found among the groups for PLT (χ

Indexed as

COVID-19Epidermal Growth FactorTransforming Growth Factor beta1AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedSARS-CoV-2Severity of Illness IndexEpidermal Growth FactorTGFB1 protein, humanTransforming Growth Factor beta1Cellular damageEpidermal growth factorİnfectionPulmonary fibrosisSARS-CoV-2Transforming growth factor-β1

Identifiers

PMID40118922
PMCPMC11928509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.